LivaNova PLC (NASDAQ:LIVN) Shares Sold by Sei Investments Co.

Sei Investments Co. lessened its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 41.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,675 shares of the company's stock after selling 38,016 shares during the quarter. Sei Investments Co. owned about 0.10% of LivaNova worth $2,439,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Cerity Partners LLC bought a new stake in LivaNova in the 3rd quarter valued at about $573,000. FMR LLC increased its stake in shares of LivaNova by 68.0% in the third quarter. FMR LLC now owns 31,466 shares of the company's stock worth $1,653,000 after buying an additional 12,735 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in LivaNova by 92.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 122,740 shares of the company's stock worth $6,449,000 after buying an additional 58,807 shares during the period. Captrust Financial Advisors bought a new position in LivaNova in the third quarter worth about $217,000. Finally, Verition Fund Management LLC boosted its holdings in shares of LivaNova by 47.4% during the 3rd quarter. Verition Fund Management LLC now owns 11,542 shares of the company's stock valued at $606,000 after buying an additional 3,710 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

LivaNova Price Performance

LIVN traded up $1.87 on Wednesday, hitting $35.72. 1,966,943 shares of the company were exchanged, compared to its average volume of 622,912. LivaNova PLC has a fifty-two week low of $32.49 and a fifty-two week high of $64.48. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The business's fifty day moving average is $41.93 and its 200 day moving average is $47.56. The firm has a market capitalization of $1.94 billion, a P/E ratio of 85.05 and a beta of 0.90.

Analysts Set New Price Targets

A number of research firms have recently issued reports on LIVN. Mizuho dropped their price target on LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 26th. Wolfe Research cut shares of LivaNova from an "outperform" rating to a "peer perform" rating in a research note on Wednesday, February 26th. Barclays decreased their price objective on shares of LivaNova from $58.00 to $56.00 and set an "equal weight" rating for the company in a research note on Friday, March 7th. The Goldman Sachs Group dropped their price objective on LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research note on Monday, March 3rd. Finally, Needham & Company LLC restated a "buy" rating and set a $64.00 price objective on shares of LivaNova in a research note on Monday, March 17th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, LivaNova presently has an average rating of "Buy" and an average price target of $61.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.